KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.85

Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study.

Rami S Komrokji, Sheida Hayati, Manuel Ugidos, Guillermo Garcia-Manero, Matteo Giovanni Della Porta, Amer M Zeidan, Valeria Santini, Uwe Platzbecker, Anita K Gandhi, Rajasekhar N V S Suragani

Am J Hematol 101(3) 427-438

PMID41549790
PMCIDPMC12868996
DOI10.1002/ajh.70171
发表日期2026-01-19
入排依据:The record describes a primary efficacy analysis from a Phase III randomized trial with a drug intervention in oncology (LR-MDS). However, the primary endpoint analyzed is RBC transfusion response, which is a categorical outcome (responder/non-responder), not a time-to-event endpoint like OS, PFS, DFS, etc. No Kaplan-Meier survival curves, hazard ratios, or time-to-event analyses are mentioned in the provided abstract.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图;FIGURE 5:非 KM 图。
摘要

摘要

The COMMANDS trial established luspatercept as a first-line treatment for anemia in transfusion-dependent lower-risk (LR) myelodysplastic syndromes (MDS). Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS trial. Of 350 evaluable patients, 238 (68.0%) had MDS with multiple lineage dysplasia and ring sideroblasts (RS) according to World Health Organization 2016 criteria, and 320 (91.4%) had somatic mutations in ≥ 1 gene (median, 2) with median variant allele frequencies (VAF) of 2%-59%. Mutation profiles were similar in the treatment groups. Luspatercept had superior responses versus epoetin alfa across multiple mutations (risk difference; RD, [95% confidence interval; CI] 0.25 [0.15-0.35]), including in SF3B1-mutated (0.38 [0.25-0.50]) and SF3B1 wild-type (0.09 [-0.11 to 0.30]). Luspatercept demonstrated superior responses in patients with VAF ≥ 10% (random effect, 0.36 [95% CI, 0.28-0.44]), and in those with 1 (63% vs. 40%; p = 0.040), 2 (70% vs. 27%; p < 0.001), and 3 (72% vs. 40%; p = 0.018) mutations, and across the low (75% vs. 38%), moderate low (61% vs. 38%), moderate high (44% vs. 21%), and high (36% vs. 24%) Molecular International Prognostic Scoring System risk groups (summary effect RD, 0.26 [95% CI, 0.14-0.37]). Across most mutations luspatercept responses were superior (random effect, 0.34 [95% CI, 0.24-0.44]) in patients with RS but were similar between treatments in RS-negative patients. Luspatercept represents an effective treatment option in various mutational backgrounds in LR MDS. Trial Registration: ClinicalTrials.gov Identifier: NCT03682536.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Mutational profile of MDS‐associated genes. (A) Mutation frequency of genes from a panel of 82 MDS‐associated genes by treatment group. (B) Boxplot of median VAF of common MDS‐associated mutations. Each boxplot depicts 1 event per patient (only those with the highest VAF for multi‐events have been included). Labels top to bottom show VAF IQR values, median VAF (%) and number of events. (C) Heat map showing correlation (Spearman correlation co‐efficient) between selected mutated genes and BL characteristics. p ≤ 0.05*, p ≤ 0.01**, p ≤ 0.001***. (D) Boxplots showing the difference in BL sEPO in patients with gene mutations that showed significant correlations with sEPO in the heat map. (E) Scatter plot of the trend between BL EPO levels and patient MB. BL indicates baseline. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure
FIGURE 2Primary endpoint response by treatment in patients with gene mutations associated with MDS. (A) In patients with mutations in MDS‐associated genes at any VAF. (B) In patients with VAF ≥ 10%. SF3B1β = SF3B1 mutation + BCOR mutation or BCORL1 mutation or NRAS mutation or RUNX1 mutation or SRSF2 mutation or STAG2 mutation. SF3B1α = SF3B1 mutation + DNMT3A mutation or TET2 mutations or ASXL1 mutation. DTA.SF3B1.wt = SF3B1 wild type + DNMT3A mutation or TET2 mutation or ASXL1 mutation.
非 KM Figure
FIGURE 3MB of genes associated with MDS and primary endpoint response to treatment. (A) Number of mutated genes in patients grouped by response and treatment. (B) Response rate by treatment and NMG. (C) Responses by treatment in patients grouped by NMG (< 2 vs. ≥ 2). NMG indicates number of mutated genes.
非 KM Figure
FIGURE 4MB at baseline by RS status. (A) By treatment group in patients with RS‐positive (RS+) and RS‐negative (RS−) disease. (B) Response to treatment by MB in patients with RS− disease. (C) Mutation profile of patients with RS− disease in the luspatercept group (left) and epoetin alfa group (right). (D) Mutation profile of patients with RS‐ disease in the luspatercept group (left) and epoetin alfa group (right). (E) Mutation profile of patients with RS+ disease in the luspatercept group (left) and epoetin alfa group (right). MB, mutational burden; RS, ring sideroblasts. [Color figure can be viewed at wileyonlinelibrary.com ]
非 KM Figure
FIGURE 5Primary endpoint response in patients grouped by the IPSS‐M for MDS. Comparison of responses by IPSS‐M risk criteria [ 12 ] between luspatercept and epoetin alfa treatment groups. Solid vertical line represents absence of treatment effect (no favorability or benefit with treatment); dotted line represents overall favorability based on the random‐effects model.
非 KM Figure